


Biomiq Delivers 58% Quarterly Sales Growth

Wednesday January 7th 2025, Coolum, Queensland: **Servatus Limited**, a global leader in microbiome skincare innovation, is pleased to report continued strong sales momentum in its fast growing skincare range, Biomiq.

Biomiq Shows Sustained Sales Strength


Biomiq recorded a 58% increase in sales, reaching \$517k for the quarter ended December (Q4 2025), driven by a strong Black Friday-Cyber Monday performance and the successful launch of our Hydrogel Face Masks in November and 5 Day Rapid Results Kits in December.



Biomiq has delivered rapid sales growth in 2025, supported by strong consumer adoption and high repeat purchase rates, with **Q4 sales increasing by more than 450% compared to the prior corresponding period in Q4 2024**.

Hydrogel Face Masks Launch

The company continued to extend its suite of products this quarter with the **launch of Hydrogel Face Masks and 5 Day Rapid Results Kits**.



These products were launched in November and December respectively and performed well in Black Friday and Cyber Monday sales as consumers extended their product range and increased their average basket value.

All of these products include Biomiq's proprietary key ingredient, BioQx, a blend of bioactive compounds including peptides, enzymes, and fatty acids that support the skin microbiome and essential functions like hydration, barrier integrity, and inflammation regulation. Its effectiveness is supported by scientific research and strong consumer repurchase rates.



Biomiq's growing commercial presence in microbiome based skincare underscores rising consumer demand for science driven solutions targeting specific skin conditions and age related changes in skin quality.

Chief Executive, Mark Williams said: "The past year has marked an exciting and deeply rewarding period of growth for Biomiq. Our strong sales performance demonstrates the power and effectiveness of our products and the excellence of our execution. This success is driven by the dedication and expertise of our scientific, manufacturing, and marketing teams, who have pioneered a microbiome based approach to skin health that I believe will define a new global category in skincare, just as probiotics transformed gut health."

Executive Director, Dr Anthony Noble commented, "Biomiq delivered accelerated sales growth in Q4 2025, underpinned by strong consumer engagement and increasing repeat purchase rates, providing clear validation of demand for microbiome based skincare. The successful launch of our hydrogel face masks and rapid results kits contributed meaningfully to revenue growth. The business continues to build a high quality, loyal customer database, with customers expanding their purchasing across the range, driving higher average basket values. Biomiq is well positioned to establish and scale a new category in microbiome based skincare."

Ends.

This release has been approved by Mark Williams & Anthony Noble for the Board of Directors



About Servatus

Servatus Limited is an Australian biotechnology company globally recognised for its leadership in live biotherapeutic drug development targeting autoimmune diseases, and for pioneering innovation in microbiome based skincare through its consumer brand Biomiq.

What is Biomiq

Biomiq is the consumer facing functional skincare brand of Servatus. Biomiq's proprietary key ingredient, BioQx, is a blend of bioactive compounds including peptides, enzymes, and fatty acids that support the skin microbiome and essential functions like hydration, barrier integrity, and inflammation regulation. Its effectiveness is supported by scientific research and strong consumer repurchase rates.

Investor Centre

All media releases and investor reports are available from our Investor Centre:

<https://www.servatus.com.au/investor-centre>

General company information can be accessed here:

<https://www.servatus.com.au/>

Biomiq product information can be accessed here:

<http://www.biomiq.com.au>